Reply to the Letter to the Editor 'Neoadjuvant radiochemotherapy and perioperative chemotherapy does not represent a standard at same priority level for oesophageal adenocarcinomas (in regard to "Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up")' by Cellini et al.

Obermannová, R; Smyth, E C

Reply to the Letter to the Editor 'Neoadjuvant radiochemotherapy and perioperative chemotherapy does not represent a standard at same priority level for oesophageal adenocarcinomas (in regard to "Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up")' by Cellini et al.

Obermannová, R; Smyth, E C.

Afiliação

Obermannová R; Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Smyth EC; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Ann Oncol ; 34(6): 554-555, 2023 06.

Article em En | MEDLINE | ID: mdl-37295906

Assuntos

Adenocarcinoma; Neoplasias Esofágicas; Humanos; Terapia Neoadjuvante; Seguimentos; Adenocarcinoma/terapia; Adenocarcinoma/tratamento farmacológico; Neoplasias Esofágicas/terapia; Neoplasias Esofágicas/tratamento farmacológico; Quimiorradioterapia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Adenocarcinoma Tipo de estudo: Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google